AACR
The firm will commercialize its Primary Immune Response assay as a laboratory-developed test to help guide immunotherapy decisions in lung cancer patients.
Recent results from the firm's case-control study cohort showed overall sensitivity of about 50 percent but higher performance for a subset of high-mortality cancers.
Oncocyte AACR Data Expands Potential Applications for Immunotherapy Response Predictor
The firm presented evidence that its DetermaIO gene expression test can help predict which bladder cancer patients are likely to respond to immune checkpoint inhibitors.
MSK Researchers Find High Prevalence of Germline Mutations in Patients With Early-Onset Cancers
The findings underscore the utility of universal germline testing in young adults diagnosed with cancers that are more common in older populations.
Pan-Cancer Screening Tests Report First Performance Numbers in Undiagnosed Cohorts
At the AACR annual meeting, researchers shared detection rate data for multi-cancer screening tests from Grail and Thrive Earlier Detection.